Trial record 1 of 1 for:
AGT-182
Safety and Dose Ranging Study of Insulin Receptor MoAb-IDS Fusion Protein in Patients With Hunter Syndrome
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT02262338 |
|
Recruitment Status :
Completed
First Posted : October 13, 2014
Last Update Posted : September 18, 2018
|
Sponsor:
ArmaGen, Inc
Information provided by (Responsible Party):
ArmaGen, Inc
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Completed |
|---|---|
| Actual Primary Completion Date : | March 27, 2017 |
| Actual Study Completion Date : | March 27, 2017 |